GFAP and Alzheimer disease: Research has identified discrepancies between astrocyte reactivity examined by 11C-deuterium-L-deprenyl (11C-DED) PET imaging and plasma GFAP levels in AD patients [5], with more significant changes observed in blood GFAP levels than in cerebrospinal fluid (CSF) GFAP levels [6].